Table 2.
Covariate | Total Cohort Model (n=3,654) | PI Model (n=2,757) | NNRTI Model (n=897) |
---|---|---|---|
| |||
OR (95% CI); P value | OR (95% CI); P value | OR (95% CI); P value | |
Race (Black vs. White) | 1.54 (1.32–1.79); <0.001 | 1.55 (1.30–1.85); <0.001 | 1.46 (1.08–1.99); 0.015 |
Sex (Female vs. Male) | 1.45 (1.23–1.70); <0.001 | 1.54 (1.28–1.86); <0.001 | 1.20 (0.87–1.64); 0.26 |
Age (Per Year Increase) | 0.98 (0.97–0.99); <0.001 | 0.98 (0.97–0.99); <0.001 | 0.97 (0.95–0.98); <0.001 |
TennCare Enrollment Criteria (Disabled vs. Othera) | 1.26 (1.08–1.46); 0.003 | 1.14 (0.96–1.35); 0.14 | 1.73 (1.28–2.34); <0.001 |
Early Medical Encounterb (Yes vs. No) | 1.05 (0.88–1.25); 0.59 | 0.97 (0.79–1.19); 0.78 | 1.32 (0.94–1.86); 0.11 |
Qualifying Drug (PI vs. NNRTI) | 0.94 (0.80–1.11); 0.45 | – | – |
Urban Residencec (Yes vs. No) | 0.97 (0.78–1.22); 0.82 | 0.95 (0.73–1.23); 0.68 | 1.06 (0.70–1.60); 0.80 |
OR: Odds ratio; CI: Confidence interval; PI: Protease inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitor;
Other includes uninsured status, aid to families of dependent children, qualified Medicare beneficiary and aged;
Defined as an outpatient visit with an HIV-related billing code within 90 days of qualifying drug prescription.